Every Spin-Off
Abridge Speciality (to be renamed Brooks Laboratories)
AnnouncedINMakes medicines under contract and loan licence for other drug companies at a plant in Baddi, Himachal Pradesh, and exports them.
Brooks Laboratories' pharmaceutical manufacturing business at Baddi: contract and loan-licence manufacturing, exports and distribution.
- Status
- Announced
- Expected
- Awaiting approvals (about 16 months)
- Parent
- Brooks Laboratories (BROOKS IN)
- Spin-off ticker
- To be announced
- Listing
- NSE and BSE
- Market
- India
- Sector
- Health care
Terms
Board approved 14 Oct 2026 a demerger of the manufacturing business into Abridge Speciality, with shareholders receiving 1 share for each Brooks share (2,94,57,248 shares of Rs 10) and a listing on BSE and NSE. Needs exchange, SEBI, NCLT and shareholder approvals; the company estimates about 16 months to listing.
Key dates
- Board approval
Source documents
- Press releaseBrooks Laboratories board outcome: demerger (14 Oct 2026, pdf)
- PresentationNot yet published
- Prospectus / demerger documentNot yet public
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email